Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Given Consensus Recommendation of “Buy” by Brokerages

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) has been assigned an average recommendation of “Buy” from the eight research firms that are covering the stock, MarketBeat.com reports. Seven investment analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $59.20.

ARCT has been the topic of a number of recent research reports. Wells Fargo & Company lowered their price target on shares of Arcturus Therapeutics from $58.00 to $50.00 and set an “overweight” rating on the stock in a research report on Friday, March 7th. Canaccord Genuity Group lowered their price target on shares of Arcturus Therapeutics from $74.00 to $68.00 and set a “buy” rating on the stock in a research report on Monday, March 10th. HC Wainwright lowered their price target on shares of Arcturus Therapeutics from $63.00 to $60.00 and set a “buy” rating on the stock in a research report on Friday, March 7th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Arcturus Therapeutics in a research report on Friday, March 7th. Finally, BTIG Research set a $48.00 price target on shares of Arcturus Therapeutics and gave the stock a “buy” rating in a research report on Monday, March 10th.

Institutional Investors Weigh In On Arcturus Therapeutics

A number of large investors have recently bought and sold shares of ARCT. Franklin Resources Inc. boosted its stake in shares of Arcturus Therapeutics by 54.6% in the 3rd quarter. Franklin Resources Inc. now owns 103,936 shares of the biotechnology company’s stock valued at $2,412,000 after purchasing an additional 36,714 shares in the last quarter. Sumitomo Mitsui Trust Group Inc. boosted its stake in shares of Arcturus Therapeutics by 45.6% in the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 2,275,715 shares of the biotechnology company’s stock valued at $52,819,000 after purchasing an additional 712,650 shares in the last quarter. Empire Life Investments Inc. boosted its stake in shares of Arcturus Therapeutics by 85.5% in the 4th quarter. Empire Life Investments Inc. now owns 279,463 shares of the biotechnology company’s stock valued at $4,742,000 after purchasing an additional 128,771 shares in the last quarter. Hennion & Walsh Asset Management Inc. boosted its stake in shares of Arcturus Therapeutics by 139.7% in the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 82,057 shares of the biotechnology company’s stock valued at $1,393,000 after purchasing an additional 47,824 shares in the last quarter. Finally, Spire Wealth Management boosted its stake in shares of Arcturus Therapeutics by 393.3% in the 4th quarter. Spire Wealth Management now owns 13,478 shares of the biotechnology company’s stock valued at $229,000 after purchasing an additional 10,746 shares in the last quarter. 94.54% of the stock is currently owned by institutional investors and hedge funds.

Arcturus Therapeutics Price Performance

Shares of ARCT opened at $14.08 on Monday. The firm has a market capitalization of $381.85 million, a PE ratio of -6.34 and a beta of 2.96. The company’s 50-day moving average is $16.64 and its 200-day moving average is $18.29. Arcturus Therapeutics has a fifty-two week low of $12.75 and a fifty-two week high of $45.00.

Arcturus Therapeutics (NASDAQ:ARCT) last issued its quarterly earnings data on Thursday, March 6th. The biotechnology company reported ($1.11) earnings per share for the quarter, missing the consensus estimate of ($0.33) by ($0.78). The company had revenue of $22.77 million during the quarter, compared to the consensus estimate of $44.64 million. Arcturus Therapeutics had a negative net margin of 36.39% and a negative return on equity of 22.39%. Analysts predict that Arcturus Therapeutics will post -2.22 earnings per share for the current fiscal year.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.